MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers18182971

Медицинская библиотека · Cancers · 2026

Immune Checkpoint Inhibitor Combinations in Advanced Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Choi Boram, Choi Youn Jin, Lee Keun Ho

СтатьяОбзорПеревод в очереди

Аннотация

BACKGROUND/

OBJECTIVES

Immune checkpoint inhibitors (ICIs) have shown limited efficacy in the treatment of ovarian cancer when used alone. This systematic review and meta-analysis evaluated the impact of different combination partners on ICI efficacy.

METHODS

PubMed, Embase, CENTRAL, and Web of Science were searched until March 2026 for phase III randomized controlled trials (RCTs) of anti-PD-1/PD-L1 combination regimens. Nine fully published trials (N = 7381) were included in the primary analyses; an ICI monotherapy trial and two conference-abstract-only trials were considered in sensitivity analyses. Hazard ratios (HRs) were pooled using random-effects models with pre-specified subgroup analyses by combination partner. Evidence certainty was assessed using GRADE.

RESULTS

Overall, ICI combination therapy significantly improved progression-free survival (PFS) (HR 0.83, 95% confidence interval (CI) 0.73-0.93; I2 = 55.8%; p = 0.007). Bevacizumab plus ICI significantly improved progression-free survival (PFS) (k = 4; HR 0.83, 95% CI 0.74-0.93 [Wald-type]; GRADE: Moderate). PARP inhibitor plus ICI also showed a Wald-type PFS improvement (k = 3; HR 0.78, 95% CI 0.63-0.96 [Wald-type]; GRADE: Low), but this was not robust to Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment or inclusion of abstract-only trials (SA5: k = 5; HR 0.85, 95% CI 0.67-1.09; I2 = 90.1%). Chemotherapy plus ICI (two avelumab trials) showed no benefit (k = 2; HR 0.96, 95% CI 0.66-1.38). KEYNOTE-B96 demonstrated the first significant overall survival (OS) benefit with an ICI regimen (HR 0.82, 95% CI 0.69-0.97). Funnel plot assessment showed no asymmetry; Egger's test was not formally applied, as the pre-specified threshold of ten trials was not met (descriptive p = 0.81).

CONCLUSIONS

ICI combination therapy improved PFS in advanced ovarian cancer, in contrast to earlier syntheses pooling monotherapy and combination regimens. The benefit was most consistent for bevacizumab-based regimens (GRADE: Moderate); the PARP inhibitor-based benefit was less robust (Low), and chemotherapy combinations offered no advantage (Very low). Subgroup differences were not statistically significant and remain exploratory; a partner-specific, biomarker-guided approach is warranted.

Для цитирования: Choi Boram, Choi Youn Jin, Lee Keun Ho. Immune Checkpoint Inhibitor Combinations in Advanced Ovarian Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Cancers. 2026. DOI: 10.3390/cancers18182971.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.